2-ethyl-6-dimethylaminepyrazine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-ethyl-6-dimethylaminepyrazine
• 英文别名: 6-ethyl-N,N-dimethylpyrazin-2-amine
• 化学式: C₈H₁₃N₃
• 分子量: 151.211
• InChiKey: FVWGKQAWTCZDTP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  三乙基氢化铋 、 N-(6-氯-2-吡嗪)-N,N-二甲胺 在 四(三苯基膦)钯 、 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 以34 mg的产率得到2-ethyl-6-dimethylaminepyrazine
  参考文献：
  名称：

  Palladium-Catalyzed Cross-Coupling Reaction of Trialkylbismuthines with 2-Haloazines and Diazines

  摘要：

  An efficient method for the cross-coupling reaction of primary trialkybismuth reagents with 2-haloazines and diazines is reported. The reaction functions with pyridines, pyrimidines, pyridazines and pyrazines and tolerates many functional groups. This method gives access to 2-alkylazines and diazines, a class of compounds which is important in medicinal chemistry.

  DOI：

  10.3987/com-13-s(s)114

文献信息

• Novel heterocyclic compounds and uses therof
  申请人：Hunag Zilin

  公开号：US20100003246A1

  公开（公告）日：2010-01-07

  New substituted heterocyclic compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

  本文提供了新的取代杂环化合物、含有它们的组合物以及使用它们抑制Raf激酶活性的方法。这些新化合物和组合物可以单独或与至少一种其他药物联合使用，用于治疗Raf激酶介导的疾病，如癌症。
• HETEROCYCLIC COMPOUNDS AND USES THEREOF
  申请人：Infinity Pharmaceuticals, Inc.

  公开号：US20150225410A1

  公开（公告）日：2015-08-13

  Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

  本文描述了调节激酶活性（包括PI3激酶活性）的化合物和药物组合物，以及与激酶活性（包括PI3激酶活性）相关的疾病和病况的治疗方法、化合物和药物组合物。
• CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF
  申请人：Intellikine, LLC.

  公开号：US20140350248A1

  公开（公告）日：2014-11-27

  Certain chemical entities that modulate PI3 kinase activity, and chemical entities, pharmaceutical compositions, and methods of treatments of diseases and conditions associated with PB kinase activity are described.
• Treatment Of Cancers Using PI3 Kinase Isoform Modulators
  申请人：Infinity Pharmaceuticals, Inc.

  公开号：US20140377258A1

  公开（公告）日：2014-12-25

  Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating cancers or hematologic disorders.
• US8129394B2
  申请人：——

  公开号：US8129394B2

  公开（公告）日：2012-03-06